Page 15 - Flipbook
P. 15
2017
Men ages 55–69
• The decision to screen for PCa should be an individual one
• The USPSTF recommends that clinicians inform men ages 55 to 69 years
about the potential benefits and harms of PSA–based screening for PCa
• Screening offers a small potential benefit of reducing the chance of dying
of PCa
• Potential harms:
• False-positive results → additional workup
• Overdiagnosis
• Overtreatment
• Treatment complications
• C Recommendation
